Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07157774 · ClinicalTrials.gov registry record · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
A Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10,450
- Enrollment target
- 20
- Study locations
NCT07157774 is a Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 10,450 participants, above the 6,940-participant average among 4 other Atherosclerotic Cardiovascular Disease (ASCVD) trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT07157774, a Phase 3 study of Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Lp(a), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10,450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Muvalaplin
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- John Muir Medical Center - Concord Campus - Concord
- Neighborhood Healthcare Institute of Health - Escondido
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Care Access - Huntington Beach - Huntington Beach
- The Cardiovascular Center - Redding
- UCLA South Bay Endocrinology - Torrance
Arizona
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC - Gilbert
- Axsendo Clinical Research - Peak Heart & Vascular - Phoenix - Phoenix
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Southwest Kidney Institute - Surprise - Surprise
- Pima Heart - Tucson
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- Legacy Clinical Trials - Colorado Springs
- OptumCare Clinical Trials, LLC - Golden
Florida
- Excel Medical Clinical Trials - Boca Raton
- FWD Clinical Research - Boca Raton
- American Research Institute - Cutler Bay
Connecticut
- Cardiology Associates of Fairfield County, P.C. - Stamford
- Chase Medical Research, LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,450 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07157774
The ClinicalTrials.gov registry entry for NCT07157774 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 10,450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 6,940-participant average among 4 other Atherosclerotic Cardiovascular Disease (ASCVD) trials with a reported enrollment target (51% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atherosclerotic Cardiovascular Disease (ASCVD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07157774 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT07157774 about?
NCT07157774 is a clinical study titled "Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)". The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.
What is the current status of trial NCT07157774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10,450 participants. The study started on 2025-09-02. Estimated completion is 2031-03.
What conditions does trial NCT07157774 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a).
What interventions are being tested in trial NCT07157774?
The interventions under investigation include: Placebo (DRUG), Muvalaplin (DRUG).
Who is sponsoring clinical trial NCT07157774?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07157774 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease (ASCVD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
RECRUITING · Phase 3
-
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
ACTIVE NOT RECRUITING · Phase 3
-
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ACTIVE NOT RECRUITING · Phase 3
-
The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.